Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 25, No 18S (June 20 Supplement), 2007: 18537
© 2007 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by El-Wahidy, G. F. Articles by Salama, M. S. Search for Related Content PubMed Articles by El-Wahidy, G. F. Articles by Salama, M. S.

Abstract

Mutant P53 in non-Hodgkin lymphoma

Faculty of Medicine, Mansoura, Egypt; Mansoura Faculty of Medicine, Mansoura, Egypt; Ain Shams University, Cairo, Egypt

18537

Background: *Chromosomal aberrations are important events in the pathogenesis of lymphoma & leukaemias P53 belongs to class of genes whose functions involves negative regulation of cell growth through certain protein synthesis which leads to arrest of the cell cycle at growth phase. *Elucidate the nature of P53 in cases with Non Hodjkins lymphoma presented in our province (North east Mediterranean) and the impact of its mutation on known prognostic factors as well as on survival of patients receiving treatment by different chemotherapy protocols. Methods: Study done on 34 patients and 10 normal contorls Conclusions: *P53 +ve mutations in patients with lymphoma outnumbered those with –ve mutations. *Positivity degree is increased in higher grade than lower grade lymphoma. *Dfs is prolonged in those with –ve mutations than in subgroups with +ve mutations. *Subgroups with negative Exon mutations carry better survival than those with +ve mutations.